SLC6A3 and SLC6A3-related dopamine transporter deficiency syndrome: Here, we demonstrate the efficacy of a novel dual combinatorial AAV-based gene therapy approach aimed at the restoration of native Slc6a3 DAT gene expression, a strategy that can provide basis for development of clinical trials for DTDS.